The Biology of Aging and Endocrine-Related Cancers: Shared Mechanisms and Interventions
The global cancer incidence in adults over 65 is expected to grow to over 20 million by 2045. This expanding cohort necessitates improved understanding of the role of aging in cancer development, treatment, and outcomes. Aging is not only a risk factor for endocrine-related cancers, but also contributes to cancer progression, therapeutic tolerance, quality of life, and survivorship. With the advancement of approaches to identify and study aging, we are better equipped to understand how aging biology influences these processes and to design ways to mitigate its effects.
This collection will focus on how aging biology affects endocrine-related cancer risk, treatment responses, and patient outcomes. Field experts will describe aging mechanisms that contribute to cancer initiation and progression, geroscience-guided pharmaceutical and behavioural interventions, the potential clinical utility of quantitative aging biomarkers, strategies to improve the outcomes of older adults with endocrine-related cancers, and special considerations for the survivorship of older adults, including disparities among minority and vulnerable populations.
The Editors welcome submissions of original research for inclusion in this collection on the following topics:
- cellular and immune senescence
- epigenetic aging
- inflammaging
- age-related changes in tumour microenvironment
- mitochondrial dysfunction, nutrient sensing, and proteostasis
- geroscience-guided interventions.
Contribute to this important field of research by submitting an original research article. For more information and to submit your proposal, please email erc@bioscientifica.com.
Collection Editors
|
|
Dr Christin E. Burd, PhD Dr Burd is a Professor of Molecular Genetics and Cancer Biology and Genetics at The Ohio State University, where she serves as Director for Translational Research for the James Comprehensive Cancer Center’s Oncogeriatrics Program. Dr Burd’s research sits at the intersect of cancer and aging, aiming to uncover the molecular pathways that contribute to cancer risk, influence treatment tolerance and efficacy, and extend the healthspan of patients with cancer. |
|
|
Dr Mina S. Sedrak, MD, MS Dr Sedrak is an Associate Professor of Medicine and Director of the Cancer and Aging Program at the David Geffen School of Medicine at UCLA. Dr Sedrak’s research is focused on understanding the mechanisms underlying cancer therapy-induced accelerated aging and, in turn, developing mechanism-based interventions to mitigate accelerated aging in cancer patients. |
